Data Sharing Statement

Shao. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia. *JAMA Oncol*. Published October 24, 2019. 10.1001/jamaoncol.2019.3692

Data
Data available: Yes
Data types: Other (please specify)
Qualified researchers may request access to individual patient-level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_d
How to access data: Qualified researchers may request access to individual patient-level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_d
When available: With publication
Document types: None
Who can access the data: Qualified researchers may request access to individual patient-level data
Types of analyses: For a specified purpose: Requests for access are assessed by an Independent Review Panel managed by the Wellcome Trust. The panel considers the scientific merit of each application. This independent group then decides whether or not the data should be provided. Once approved, data are available for up to 24 months.
Mechanisms of data availability: After approval of request: For a specified purpose: Requests for access are assessed by an Independent Review Panel managed by the Wellcome Trust. The panel considers the scientific merit of each application. This independent group then decides whether or not the data should be provided. Once approved, data are available for up to 24 months.
Any additional restrictions: Roche reserves the right to protect our commercially sensitive information or that of third parties with whom we have contractual obligations.